Single Center Experience of Percutaneous Septal Ablation in Patients With Hypertrophic Cardiomyopathy With A Novel Agent: Polidocanol
Section snippets
Methods
In this observational study, all consecutive patients with drug-refractory symptomatic OHCM who were appropriate for percutaneous septal reduction therapy were enrolled between January 2017 and June 2021. The patients were eligible (1) if they had HCM with severe LVOT obstruction on transthoracic echocardiography defined as LVOT gradient >30 mm Hg at rest or >50 mm Hg with physiologic provocation such as Valsalva maneuver, and (2) if they had symptoms attributable to LVOT obstruction despite
Results
A total of 28 patients were included in this study. Median age of the study population was 61 (43.5-67) years, and 9 patients (32.1%) were female. Hypertension was present in 10 (35.7%) cases, diabetes mellitus was present in 5 (17.9%) cases, and atrial fibrillation was present in 8 patients (28.6%). Most patients were under treatment with β-blockers (%82.1), and 7 patients (25%) were using calcium channel blockers. Only 2 cases were under combined treatment with both β-blocker and calcium
Discussion
Our study indicates that polidocanol is a safe and effective alternative agent for septal ablation in patients with HCM. Early outcomes are encouraging, and complication rates are similar to ASA.
Surgical myectomy is still the first-line recommendation in patients with HCM who have refractory symptoms under optimal medical treatment. However, ASA is defined as an alternative option for patients who are not fit for surgery or refuse surgery. There are several studies demonstrating the efficacy of
Disclosures
The authors have no conflicts of interest to declare.
References (19)
- et al.
Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of endorsement
J Am Coll Cardiol
(2017) - et al.
Polidocanol injection for chemical delay and its effect on the survival of rat dorsal skin flaps
J Plast Reconstr Aesthet Surg
(2014) - et al.
Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months’ follow-up in 19 patients
J Am Coll Cardiol
(2011) - et al.
Safety testing of alkyl polyethoxylate nonionic surfactants. I. Acute effects
Food Cosmet Toxicol
(1977) - et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation
(2011) - et al.
Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes
Circ Cardiovasc Interv
(2019) - et al.
Glue septal ablation: a promising alternative to alcohol septal ablation
JRSM Cardiovasc Dis
(2016) - et al.
Evaluation of the sclerotherapeutic efficacy of ethanol, polidocanol, and OK-432 using an in vitro model
Dermatol Surg
(2007) - et al.
Brockenbrough-Braunwald-Morrow sign and Valsalva manoeuvre: how to unmask dynamic left ventricular outflow tract obstruction
Eur Heart J Cardiovasc Imaging
(2022)
Cited by (0)
Funding: None.